We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbD Serotec and BBInternational Announce Cooperation and Co-Marketing Agreement
News

AbD Serotec and BBInternational Announce Cooperation and Co-Marketing Agreement

AbD Serotec and BBInternational Announce Cooperation and Co-Marketing Agreement
News

AbD Serotec and BBInternational Announce Cooperation and Co-Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbD Serotec and BBInternational Announce Cooperation and Co-Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AbD Serotec, a Division of MorphoSys AG, Munich, and BBInternational (BBI) have announced the start of a co-marketing agreement between the two companies. Within the scope of this agreement the parties agree to co-market each others products and services to their world-wide customer bases. Financial details of the agreement were not disclosed.

The agreement will allow BBI customers access to more than 13,000 antibodies and immunological reagents, custom monoclonal antibodies developed from the MorphoSys HuCAL library, and large and small scale antibody production and conjugation services from AbD Serotec.

AbD Serotec antibody customers will have the advantage of direct access to BBI’s complementary range of services for production of gold-labeled reagents, contract research and development, and manufacture of diagnostic tests for the Point of Care (POC) markets.

BBI developed a unique 'in-house' process for the manufacture of superior quality gold nanoparticles in 1986 and has since grown into a major supplier of products and services to a global customer base, ranging from the supply of bulk gold colloid through to high volume manufacture of rapid tests. BBI operates from its headquarters in South Wales, along with further development and manufacturing services from facilities in Dundee, Scotland, and Madison, Wisconsin, USA, and is the partner of choice for many global blue chip diagnostic companies.

“BBI customers often discuss their antibody selection with us when choosing their gold reagents, so it is an advantage for us to be able to recommend a leading supplier. AbD Serotec has worked with BBI on a number of antibody-gold conjugations, and we have always been impressed with the level of service and quality range of products. We look forward to working with the AbD Serotec team and increasing the convenience for BBI customers.” commented Leigh Thomas, Sales Manager of BBI.

Dieter Feger, Head of AbD Serotec and Senior Vice President of MorphoSys AG, added, “AbD Serotec prides itself on its commitment to providing its customers with the highest quality products and services. BBI is globally recognized as a supplier of superior quality gold reagents for use in lateral flow rapid diagnostic tests, so we are very excited about gaining access to BBI technology and services for our customers.”
Advertisement